Prof. Andrés Ferreri | ICML 2017 | Extranodal Marginal Zone Lymphoma and the use of clarithromycin

By Anne Villeneuve, Natasha Fort

Featured

Andrés Ferreri

Jun 22, 2017

Prof. Andrés Ferreri, from the San Raffaele Scientific Institute, Milan, IT, on the use of clarithromycin in Extranodal Marginal Zone Lymphoma:

Extranodal Marginal Zone Lymphoma and the use of clarithromycin

More about...

ICML 2017 Indolent B-cell lymphomas Marginal zone lymphoma Rare lymphomas

What is the familial risk of developing a hematological malignancy?

This article provides a summary of a study by Amit Sud and colleagues, which aimed to investigate the familial risks in hematological malignancies using a large database registry in...

Sep 9, 2019

What is the familial risk of developing a hematological malignancy?

This article provides a summary of a study by Amit Sud and colleagues, which aimed to investigate the familial risks in...

Sep 9, 2019

ICML 2019 | Can CAR T therapy deliver long-term benefits for patients with NHL?

During ICML 2019 in Lugano, CH, the Lymphoma Hub were pleased to speak to Sattva Neelapu from MD Anderson Cancer Center, Houston, US, about the potential of CAR T therapy...

Jun 28, 2019

ICML 2019 | Can CAR T therapy deliver long-term benefits for patients with NHL?

During ICML 2019 in Lugano, CH, the Lymphoma Hub were pleased to speak to Sattva Neelapu from MD Anderson Cancer Center,...

Jun 28, 2019

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Prof. Andrés Ferreri | ICML 2017 | Extranodal Marginal Zone Lymphoma and the use of clarithromycin

By Anne Villeneuve, Natasha Fort

Featured

Andrés Ferreri

Jun 22, 2017

More about...

Related articles

Sep 9, 2019

Sep 9, 2019

Jun 28, 2019

Jun 28, 2019

Newsletter